Compare BOTJ & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOTJ | ACET |
|---|---|---|
| Founded | 1998 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.0M | 42.0M |
| IPO Year | 2015 | 2017 |
| Metric | BOTJ | ACET |
|---|---|---|
| Price | $29.50 | $4.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $34.83 |
| AVG Volume (30 Days) | 37.8K | ★ 296.1K |
| Earning Date | 11-06-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.39% | N/A |
| EPS Growth | ★ 13.71 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | ★ $4,273,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.86 | ★ N/A |
| Revenue Growth | ★ 6.74 | N/A |
| 52 Week Low | $15.72 | $0.46 |
| 52 Week High | $29.13 | $9.97 |
| Indicator | BOTJ | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 77.26 | 22.66 |
| Support Level | $26.08 | N/A |
| Resistance Level | N/A | $9.67 |
| Average True Range (ATR) | 0.65 | 0.42 |
| MACD | 0.24 | -0.07 |
| Stochastic Oscillator | 93.92 | 0.71 |
Bank of the James Financial Group Inc is a bank holding company that provides retail and commercial banking, deposit services, lending services, mortgage brokerage services, and other banking services. The company provides a range of deposit services including checking accounts, savings accounts and other time deposits of various types, ranging from daily money market accounts to longer-term certificates of deposit. It offers various types of secured and unsecured consumer loans, including personal loans, lines of credit, overdraft lines of credit, automobile loans, installment loans, demand loans, and home equity loans. It operates three business segments community banking; mortgage banking, and investment advisory services.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).